Key Highlights

  • Shares traded 3.81% higher at USD 263.10 on Friday, November 13, 2026, per market data, and no company announcement dated November 11 to 13 surfaced to explain the advance.
  • Fiscal second-quarter Revenue reached USD 1.6 billion, a 9% increase. Adjusted diluted EPS was USD 2.94, up from USD 2.47, and GAAP diluted EPS rose to USD 2.19 from USD 1.94.
  • Fiscal 2027 adjusted Earnings guidance now spans USD 11.35 to 11.55, replacing USD 11.10 to 11.30, and roughly USD 0.18 of that lift stems from Tariff refunds collected so far this year.
  • Life Sciences sales increased 18% to USD 170.6 million, and the segment's full-year organic growth view moved up to a band of 9% to 10%, previously 6% to 7%.

Fiscal Second-Quarter Beat Sets Up a Raised Forecast

STERIS (NYSE:STE) traded at USD 263.10 on Friday, November 13, 2026, up 3.81% in market data. Nothing dated November 11 to 13 appears to account for that, so the latest verified development is the fiscal second-quarter report issued November 4, 2026. The infection prevention and sterilization group generated revenue of USD 1.6 billion, rising 9% (8% organically at constant currency). GAAP Net Income stood at USD 213.7 million, equal to USD 2.19 a share, versus USD 191.9 million or USD 1.94. Adjusted net income reached USD 286.8 million, or USD 2.94 per share, compared with USD 2.47.

Tariff Refunds Prop Up the Upgrade

Within STERIS (NYSE:STE), tariff refunds lifted the quarter by about USD 20 million before tax, and roughly USD 0.18 of the higher adjusted earnings guide comes from refunds received this year. Without them, the guide would sit near USD 11.17 to 11.37 (calculated), barely above the earlier USD 11.10 to 11.30. Published coverage noted that a single Life Sciences order over USD 10 million helped the period and will not repeat, and that refunds added roughly 130 basis points to the 45.3% adjusted gross margin. In Applied Sterilization Technologies, segment revenue hit USD 295.6 million (up 5%), while its organic growth outlook, previously 7% to 8%, now reads 6% to 7%.

Lower Cash Generation and an Acquisition Still Pending

Operating cash flow at STERIS (NYSE:STE) for the first half of the fiscal year reached USD 656.1 million, down from USD 707.8 million. Free cash flow followed a similar path, at USD 492.5 million compared with USD 527.7 million, largely because Working Capital contributed far less. A restructuring program, mainly in Healthcare, involves about USD 45 million in charges and roughly USD 9 million of annualized savings. The Xodus Medical acquisition is still pending and excluded from guidance until closing, and published reports cite about USD 2.1 billion for the price. At USD 263.10, the stock trades near 23 times the midpoint of adjusted earnings guidance (calculated).

Where Things Stand

There is no identifiable company-specific trigger for Friday's 3.81% gain, so the move is best regarded as unexplained. STERIS (NYSE:STE) recently topped revenue and adjusted earnings forecasts and raised its fiscal 2027 outlook, but partly because of one-time tariff refunds and a Life Sciences order that, per published coverage, will not recur. Cash flow is weaker this year, and a debt-financed deal is awaiting completion. Figures are live and may reverse. Watch closing of the Xodus Medical transaction, Demand in Applied Sterilization and realized restructuring savings.